Abstract
Chronic diabetic wound injury is a serious syndrome of diabetes, and the treatment of this syndrome is of great significance. Owing to metabolic abnormalities, diabetic wounds are difficult to heal due to chronic inflammation, immune dysfunction, impaired angiogenesis and bacterial reproduction. However, most traditional treatments can only play a limited role in dealing with unhealed wounds, and the overall healing effect is not ideal. We designed a novel bone marrow mesenchymal stem cell-derived exosome (MSC-Exo)-loaded carboxyethyl chitosan (CEC)-dialdehyde carboxymethyl cellulose (DCMC) hydrogel (MSC-Exos@CEC-DCMC HG) for chronic diabetic wound healing. The results demonstrated that CEC can be cross-linked with DCMC through Schiff base reactions to form antibacterial and self-healing hydrogels. The inherent MSC-Exos not only promoted angiogenesis but also enhanced the transformation of M1-type macrophages to the M2 type to reduce inflammatory effects. Finally, MSC-Exos@CEC-DCMC HG, as an effective therapeutic agent, synergistically adjusted the wound inflammation microenvironment, promoted neovascularization, and accelerated wound healing in type 1 diabetic rats.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
